Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells

Circulation

Volumn 96, Issue 9, 1997, Pages 2868-2876

  Schneider, David J ^a   Absher, P Marlene ^b   Ricci, Michael A ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b NONE

Author keywords

Arteries cells; Insulin; Plasminogen activators

Indexed keywords

INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; CELL PROLIFERATION; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; SWINE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0030723973     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.9.2868     Document Type: Article

References (41)

1. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82:27-36.
2. Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, Stamler R, Stamler J. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary-heart disease mortality in men and women. Am J Epidemiol. 1986;123:504-516.
3. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672-676.
4. Modan M, Or J, Karasik A, Drory Y, Fuchs Z, Lusky A, Chetrit A, Halkin H. Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease. Circulation. 1991;84:1165-1175.
5. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
6. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism. 1986;35: 250-253.
7. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988;8:68-72.
8. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
9. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab. 1987;13:331-336.
10. Jansson JH, Johansson B, Boman K, Nilsson TK. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med. 1991;229:309-316.
11. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA. 1991;88:9959-9963.
12. Fattal PG, Schneider DJ, Sobel BE, Billadello JJ. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem. 1992;267:12412-12415.
13. Nordt TK, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 (PAI-1) by precursors of insulin: a potential risk factor for vascular disease. Circulation. 1994;89:321-330.
14. Alessi MC, Juhan-Vague I, Kooistra T, DeClerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemost. 1988;60:491-494.
15. Kooistra T, Bosma PJ, Tons HAM, Van Den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989;62:723-728.
16. Kristensen PL, Larsson LI, Nielsen LS, Grondahl-Hansen J, Andreasen PA, Dano K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 1984;168:33-37.
17. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): a new member of the serpin gene family. EMBO J. 1986;5:2539-2544.
18. Mayer EJ, Fujita T, Gardell SJ, Shebuski RJ, Reilly CF. The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. Blood. 1990;76:1514-1520.
19. Alessi MC, Anfosso F, Peiretti HF, Nalbone G, Juhan-Vague I. Upregulation of PAI-1 synthesis by insulin and proinsulin in HepG2 cells but not in endothelial cells. Fibrinolysis. 1995;9:237-242.
20. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes. 1992;41:890-895.
21. Klassen KJ, Nordt TK, Schneider DJ, Sobel BE. Constitutive biosynthesis of plasminogen activator inhibitor type 1 (PAI-1) by cultured human aortic endothelial cells independent of insulin. Coron Artery Dis. 1993;4:713-719.
22. Van Hinsbergh VWM, Binnema D, Sheffer MA, Sprengers ED, Kooistra T, Rijken DC. Production of plasminogen activators and inhibitors by serially propagated endothelial cells from adult human blood vessels. Arteriosclerosis. 1985;7:389-400.
23. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. J Biol Chem. 1989;264:10396-10401.
24. Compton SJ, Jones CG. Mechanism of dye response and interference in the Bradford protein assay. Anal Biochem. 1985;151:369-374.
25. Cesarone CF, Bolognesi C, Santi L. Improved microfluorometric DNA determination in biological material using 33528 Hoechst. Anal Biochem. 1979;100:188-197.
26. DeClerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988;71:220-225.
27. 4. Nature. 1970;39:680-682.
28. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-161.
29. White BA, Bancroft, FC. Cytoplasmic dot hybridization. J Biol Chem. 1982;257:8569-8572.
30. Defronzo RA. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes. 1988;37:667-687.
31. Defronzo RA. Insulin secretion, insulin resistance, and obesity. Int J Obesity. 1982;6(S1):73-82.
32. Modan MH, Halkin S, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia: a link between hypertension obesity and glucose intolerance. J Clin Invest. 1980;66:763-772.
33. Steil GM, Ader M, Moore DM, Rebrin K, Bergman RN. Transendothelial insulin transport is not saturable in vivo: no evidence for a receptor-mediated process. J Clin Invest. 1996;97:1497-1503.
34. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation. 1996;93:106-110.
35. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest. 1996;97:37-46.
36. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;11:183-190.
37. Mansfield MW, Strickland MH, Grant PJ. Plasminogen activator inhibitor (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost. 1995; 74:837-841.
38. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995;44: 37-42.
39. Stein B, Weintraub WS, Gebhart SSP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JS, Morris DC, King SP. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995; 91:979-989.
40. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335: 217-225.
41. Sobel BE. Potentiation of the vasculopathy by insulin: implications from an NHLBI clinical alert. Circulation. 1996;93:1613-1615.